SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 2.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.
| DEAL STATS | # |
|---|---|
| Overall | 170 of 170 |
| Sector: Business Services M&A | 14 of 14 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 54 of 54 |
| Country: Netherlands M&A | 42 of 42 |
| Year: 2025 M&A | 6 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-24 |
Alpine
Utrecht, Netherlands Alpine is a hearing protection brand, marketing premium products around the globe. Alpine was founded in 1994 and is based in Utrecht, Netherlands. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-22 |
Imcheck Therapeutics
Marseilles, France ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France. |
Sell | - |